Lisa Barroilhet, MD, of the UW Ob-Gyn Division of Gynecologic Oncology, co-authored an article published in the June 2020 edition of Gynecologic Oncology!
“A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma” shares data collected from an open-label, randomized, multi-site, phase 2 trial comparing two different modes of treatment for cancer. Patients were randomly assigned to receive only gemcitabine, or to receive gemcitabine plus pazopanib.
“The addition of paz to gem enhanced anti-tumor activity; those with platinum-resistant disease derived the most benefit from combination therapy, even in the setting of receiving prior bevacizumab.”
Read the whole article here!